Intestinal Glucagon-like Peptide-1 (GLP-1) and the Physiological Role in Eating in Humans

• Status: Completed
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: Male

Summary

The aim is to further establish a physiological role for GLP-1 as an endogenous satiety signal by examining the effect of the specific GLP-1 receptor antagonist exendin (9-39) on appetite and food intake in healthy male subjects.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: University Hospital, Basel, Switzerland
• Treatments: Glucagon; Glucagon-Like Peptide 1

Criteria

Inclusion Criteria:

1. Healthy male subject with a BMI of 19-25 m2/kg

2. Stable body weight for at least three months

3. Normal eating habits

4. Age between 18 and 45 years

5. Sufficient understanding of the German language

6. Subjects understand the procedures and the risks associated with the study

7. Participants must be willing to adhere to the protocol and sign the consent form

Exclusion Criteria:

1. Participation in another clinical trial (currently or within the last 30 days)

2. Smoking

3. Substance abuse

4. Regular intake of medications (except for oral contraceptives)

5. Chronic or acute medical condition including clinically relevant abnormality in physical exam or laboratory values

6. History of gastrointestinal disorders

7. Food allergies